ANGPTL3, identified as a promising lipid-lowering therapy for atherosclerotic cardiovascular disease through the regulation of lipoprotein metabolism and lipid levels [48], may also serve as a potential therapeutic target for kidney injury mediated by dyslipidemia. The gene discussed is ANGPTL3; the disease is metabolic syndrome.